ArticleEsophagus : official journal of the Japan Esophageal Society2026
The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma.Cancer biology & therapy · 2026Review
- Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study.Cancer immunology, immunotherapy : CII · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsNivolumab plus ipilimumab (Nivo + Ipi) is recommended as the first-line standard treatment for patients with advanced esophageal squamous cell carcinoma (aESCC), taking into consideration the patient's general condition and Programmed cell death ligand 1 (PD-L1) expression. In the CheckMate 648 (CM648) trial, the incidence of treatment-related adverse events (TRAEs) of any grade and grade ≥ 3 were reported to be 80% and 32%, respectively, among patients who received Nivo + Ipi Still, it is occasionally given to patients with frail general conditions or as salvage-line treatment. However, there was little data on safety and efficacy in real-world settings.
methodsWe retrospectively analyzed the data of patients who received Nivo + Ipi for aESCC between 2022 and 2023 in our hospital. We evaluated immune-related AEs (irAEs), overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
resultsThirty patients were subjected to this study. The patients' characteristics were as follows: median age (range): 63.5 (36-80) years, ECOG PS 0/1 ≤ : 16/14, treatment-line 1st/2nd or later: 6/24. Eight of 30 patients who experienced grade 2 or higher irAE required systemic steroid therapy. Four of 8 patients required additional treatment following the initial steroid therapy, two with increased steroid dose, one with mycophenolate mofetil (MMF), and one with steroid pulse therapy plus MMF. The ORR, median PFS, and median OS were 66.7%, 11.0 months, and 15.4 months in the 1st-line group and 36.8%, 2.6 months, and 10.2 months in the 2nd or later-line group, respectively.
conclusionsOur study showed a safety profile comparable to that of CM648 trial. Nivo + Ipi as 2nd or later-line treatment demonstrated promising efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.